
96.29 BATS BZX Real-Time Price As of 3:48pm ET | ![]() Today’s Change | 16.75 Today|||52-Week Range 121.16 | +5.89% Year-to-Date |
FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses Feb 25 / Zacks.com - Paid Partner Content | Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar? Feb 17 / Zacks.com - Paid Partner Content |
Fate Therapeutics Inc (FATE) Q4 2020 Earnings Call Transcript Feb 25 / MotleyFool.com - Paid Partner Content |
Previous close | 96.64 |
Today’s open | 95.96 |
Day’s range | 93.51 - 98.78 |
Volume | 77,692 |
Average volume (3 months) | 1,078,869 |
Market cap | $8.4B |
Earnings growth (last year) | -46.22% |
Earnings growth (this year) | +10.04% |
Earnings growth (next 5 years) | -11.43% |
Revenue growth (last year) | +194.33% |
P/E ratio | NM |
Price/Sales | 238.32 |
Price/Book | 20.51 |
Today’s change | Today’s % change | |
---|---|---|
ARWRArrowhead Pharmaceut... | -3.03 | -3.62% |
XLRNAcceleron Pharma Inc | -3.72 | -2.65% |
CRSPCRISPR Therapeutics ... | +0.07 | +0.05% |
NBIXNeurocrine Bioscienc... | -7.96 | -7.26% |
Next reporting date | May 12, 2021 |
EPS forecast (this quarter) | -$0.43 |
Annual revenue (last year) | $31.4M |
Annual profit (last year) | -$173.4M |
Net profit margin | -551.59% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |